Serum matrix metalloproteinase-9 levels and cardiovascular risk rates in subjects with metabolic syndrome
Acta Medica Mediterranea, cilt.31, sa.6, ss.1271-1276, 2015 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 6
- Basım Tarihi: 2015
- Dergi Adı: Acta Medica Mediterranea
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1271-1276
- Anahtar Kelimeler: Metabolic syndrome, Framingham Risk Score, Matrix Metalloproteinase-9, Atherosclerosis, Cardiovascular risk
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: The present study aimed to evaluate and to compare Framingham Risk Score (FRS), a prediction tool for 10- year risk of coronary heart disease, and Matrix Metalloproteinase-9 (MMP-9) levels (an atherosclerotic proinflammatory marker) in patients with metabolic syndrome (MetS). Materials and methods: We included 86 subjects (51 patients with MetS and 35 healthy controls) in this study. Age, body mass index (BMI), waist circumference, detailed medical records (of them and their family as well) of all subjects were noted. Insulin, fasting blood glucose, Homeostatic Model Assessment- Insulin resistance (HOMA-IR), total cholesterol, low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and triglyceride levels were determined. Also, blood samples for MMP-9 levels were taken. FRS was calculated for each subject according to obtained data. Results: The mean age of the all participants was 38.52 ± 10.02 years (range: 20 - 55 years). FRS was higher in the MetS group than the control group (1.83 ± 1.49 and 1.20 ± 0.72 %; p < 0.017). Also MMP-9 levels were higher in the MetS group than control group (84.64 ± 46.85 and 45.94 ± 19.31 pg/mL; p < 0.001). There was no statistically significant relationship between groups in respect of FRS and MMP-9 levels (p > 0.05). Conclusion: In this pilot study, increased inflammation in MetS patients by measuring MMP-9 levels has been detected. The optimal cut-off value of MMP-9 to predict metabolic syndrome was determined as =76 ng/mL. However it was not correlated with FRS. Due to the uncorrelated information between MMP-9 and FRS further studies are needed to improve the predictive power of FRS.